A leading weight-loss drug company, Eli Lilly, is rumored to be rushing into “psychedelic drugs”! It wants to acquire ATAI, with the share price surging 66%. Why have mind-altering drugs suddenly become hot?

Big Pharma is officially reaching out to psychedelics. According to Bloomberg, Eli Lilly, the leader in weight-loss injections, is in talks to acquire the psychedelic startup AtaiBeckley (ATAI). The deal could be finalized as early as this week, and a piece of news sparks one thing after another: ATAI’s after-hours stock price surged 66%. Lilly is one of the two major giants behind GLP-1 weight-loss injections—now it is extending its reach toward psychedelics, which were once considered taboo. Behind this is an entire set of regulatory and capital headwinds shifting. Why did psychedelic drugs suddenly become the next gold mine in the eyes of Wall Street and pharmaceutical companies in 2026?
（Background: Anthropic announced “developing new drugs in-house,” and experts poured cold water: FDA certification is still at least 10 years away）
（Background added: Research—can slimming injections fix women’s “employment problem”? And the odds of dating a new partner also spike）

Table of contents

Toggle

• FDA compresses a ten-month review into one to two months
• Clinical data finally gets solid
• Drugmakers look for the next growth curve after GLP-1

Key takeaways

• Lilly is in discussions to acquire psychedelic startup AtaiBeckley; ATAI jumps 66% after hours, and a major pharma firm doubles down on psychedelics for the first time
• The FDA issues “National Priority Review Vouchers” for 3 psychedelic drugs, cutting a 10 to 12-month review down to 1 to 2 months
• Compass Pathways hits primary endpoints in two consecutive Phase 3 trials; the psilocybin therapy could get FDA approval as early as early 2027

Big Pharma is officially reaching out to psychedelics, developing the next generation of drugs to treat mental illnesses. According to Bloomberg, Eli Lilly, one of the largest drugmakers by global market value and a leader in weight-loss injections, is discussing the acquisition of psychedelic startup AtaiBeckley (ATAI). The deal could be finalized as early as this week. AtaiBeckley’s stock surged 66% after hours, while Lilly’s shares remained relatively steady.

AtaiBeckley is no small company. It was formed in 2025 through the merger of atai Life Sciences and the UK’s Beckley Psytech, headquartered in New York. One of its key backers is Silicon Valley venture capital godfather Peter Thiel. What the company focuses on is developing prescription drugs for treatment-resistant depression and post-traumatic stress disorder (PTSD) using substances once labeled “drugs,” such as psilocybin (the active ingredient in psychedelic “magic mushrooms”) and MDMA (commonly known as “ecstasy”). A weight-loss-injection giant going to buy a psychedelic company—this combination would have been nearly unimaginable three years ago.

FDA compresses a ten-month review into one to two months

Why psychedelic drugs suddenly became a hot commodity had its first spark literally lit by the government. On April 18, 2026, Trump signed an executive order requiring federal agencies to accelerate research, review, and approval of psychedelic therapies for major mental illnesses, and also allocated $50 million in grants for state governments to fund related research.

Then on April 24, the FDA issued “National Priority Review Vouchers” for three psychedelic drugs, compressing what would originally be a 10 to 12-month new drug review directly down to 1 to 2 months. The three are two psilocybin drugs for treatment-resistant depression and one PTSD therapy, methylone, which is structurally similar to MDMA.

What’s absurd is that under U.S. federal law, these drugs are still “Schedule I controlled substances,” on the same tier as heroin. The official definition is “high risk of abuse, no currently accepted medical use.” Saying there is no medical use while pushing them through a fast track precisely reflects how quickly the tide is turning.

FDA Commissioner Marty Makary put it plainly: he said the government “owes U.S. veterans and all suffering patients a commitment,” and that it will evaluate these therapies with the most urgent mindset.

Clinical data finally gets solid

Policy alone isn’t enough; what truly makes capital willing to bet is solid clinical evidence. Compass Pathways, a UK psychedelic company, and its psilocybin therapy COMP360, met endpoints in two consecutive Phase 3 clinical trials. COMP005 in June 2025 and COMP006 in February 2026 both hit their primary efficacy endpoints, with strong statistical significance. This is the first time in U.S. regulatory history that a classic psychedelic compound has reached this stage for a psychiatric indication.

It’s also worth noting that COMP360 does not have patients ingest mushrooms themselves. Instead, standardized doses are administered as a single session in a clinical setting under healthcare supervision, along with psychological support. Compass Pathways plans to file a new drug application in the fourth quarter of 2026. With that priority review voucher in hand, the market expects the therapy could receive FDA approval as early as early 2027, with a chance to become the first psychedelic therapy ever formally approved for commercial sale.

Drugmakers hunt for the next growth curve after GLP-1

For drugmakers at Lilly’s level, buying a psychedelic company is actually a calm business calculation. GLP-1 weight-loss injections (Lilly’s Zepbound and Novo Nordisk’s Wegovy) have long been cash-printing machines, but Wall Street always asks, “What’s the next growth story?” Mental health is a massive market with long-term shortages.

Hundreds of millions of people worldwide suffer from depression. Among them, patients with treatment-resistant depression respond poorly to existing antidepressants and have limited options. Multiple research institutions estimate that the psychedelic drugs market will grow from several billions of dollars in 2026 to $13 to $23 billion within the next decade. A field that mainstream drugmakers once tried to avoid at all costs is now becoming a battleground.

From the psychedelic symbols in the hands of hippies in the 1960s to prescription drugs that Wall Street is rushing to invest in in 2026—psychedelics have taken a long road to reclaim legitimacy. If Lilly’s acquisition succeeds, it will amount to stamping the entire industry with the badge of “certified by Big Pharma.” The contradiction of “illegal” at the federal level coexisting with “fast-track approval” has not been resolved yet. The answers on post-approval pricing, insurance coverage, and abuse concerns are still missing. But one thing is certain: psychedelics are no longer just a product of counterculture—they are steadily moving into the prescription charts of pharmacies.

Frequently asked questions

Why did psychedelics suddenly become popular in 2026?

In April, Trump signed an executive order to accelerate reviews; the FDA issued priority review vouchers to compress approval timelines to 1 to 2 months; and Compass Pathways hit primary endpoints in Phase 3 trials twice in a row, prompting capital and major pharma to bet on therapeutic psychedelics.

Are psychedelics legal in the United States?

Most psychedelics (LSD, psilocybin, MDMA) are still Schedule I controlled substances under federal law and are deemed to have no currently accepted medical use, but the FDA is fast-tracking review of prescription-drug versions for treating depression and PTSD.